Safety of BI 1358894 in patients with major depressive disorder: Results and learnings from a phase II randomized decentralized clinical trial
Christopher Reist, Peide Li, Thuy Le Nguyen, Sigurd D. Süssmuth · 2024
Read Safety of BI 1358894 in patients with major depressive disorder: Results and learnings from a phase II randomized decentralized clinical trial by Christopher Reist, Peide Li, Thuy Le Nguyen, Sigurd D. Süssmuth (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11665782.txt.
Description
Christopher Reist, Peide Li, Thuy Le Nguyen, and Sigurd Süssmuth report on a fully remote drug trial for major depression, in this 2024 paper. The trial tested a compound called BI 1358894 against placebo in patients whose first antidepressant had not worked well enough. Running the whole trial from patients' homes was itself part of the test.
The remote process worked as planned, and most patients rated the experience well. But sign-ups fell short despite wide outreach, and the trial ended early with only forty-five patients assigned. Side effects were common in both groups. The authors share lessons on loosening entry rules, improving recruitment, and using digital tools wisely, so future home-based trials can fill their rosters.
Catalog record
| CREATOR | Christopher Reist, Peide Li, Thuy Le Nguyen, Sigurd D. Süssmuth |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |